Skip to main content

Rights Offerings

Updated Jun 24, 2026 at 2:35pm

Research Draft Medium 1,284 words

A rights offering (also "rights issue") is a way for a company to raise new equity by giving its existing shareholders the right — but not the obligation — to buy newly issued shares at a fixed, usually discounted price, in proportion to their current holdings. Its defining tension: because the new shares are offered first to current owners, a rights issue is, in principle, the cheapest and least dilutive way to raise equity and the fairest to incumbents — yet in the United States it has all but vanished, displaced by underwritten secondary offerings. That gap between theoretical efficiency and actual usage is the central puzzle of the topic and is known as the "rights offer paradox."

How it's formed

A rights offering is defined by a handful of terms set by the issuer (and, where applicable, its regulator):

  • Subscription ratio — how many rights are needed to buy one new share, expressed against existing holdings (e.g., a "1-for-5" issue grants one right per five shares held; a "3-for-2" grants enough rights to buy three new shares per two held). Wikipedia's example uses three rights per two shares.
  • Subscription price — the fixed price per new share, typically set at a meaningful discount to the prevailing market price to incentivise take-up.
  • Record date / ex-rights date — the record date determines who is entitled to rights; on the ex-rights date the stock begins trading without the attached right, and the price adjusts downward.
  • Subscription period — a short window, commonly two-to-four weeks, during which rights must be exercised or they expire worthless.

The discounted price mechanically lowers the share price, so it is not a "free" gift — it is offset by dilution. The reference price after the issue is the theoretical ex-rights price (TERP):

> TERP = (market value of existing shares + cash raised from new shares) ÷ total shares after the issue.

The value of one right can then be approximated as the difference between the cum-rights price and TERP, scaled by the ratio — equivalently (cum-rights price − subscription price) ÷ (rights needed per new share + 1). These are standard textbook identities; in practice the right trades at its own supply-and-demand price, which deviates from theory because of time value, volatility, and liquidity.

Renounceable vs. non-renounceable. If rights are renounceable (transferable), a shareholder who does not want to subscribe can sell the rights on-market — they often trade "nil-paid" on the same exchange during the subscription period. This lets a non-participating holder recoup the value lost to dilution. Non-renounceable rights cannot be sold; a holder who does nothing simply suffers dilution. Many offerings add an oversubscription privilege, letting subscribing holders apply for shares left unclaimed by others.

Underwriting/backstop. Issuers frequently hire an investment bank to standby underwrite — committing to buy any unsubscribed shares (a "backstop") — to guarantee the proceeds. This is the link to the paradox below.

How it's used in practice

Rights offerings are used when a company needs new equity and wants (or is legally required) to honour shareholders' pre-emption rights — the right of first refusal on new shares that protects against dilution. This is the dominant SEO method across much of Europe, the UK, and many Asian markets, where pre-emption rights are strong by law or listing rule.

They cluster around specific situations: recapitalising a stressed balance sheet, funding an acquisition, meeting bank or regulatory capital requirements (common for banks and REITs), or as a financing of last resort when a company cannot easily place stock with new institutions. Deeply discounted "rescue rights issues" are a recognisable distress signal.

For an existing holder the decision is simple in arithmetic: subscribe (maintain ownership, supply cash), sell the rights (if renounceable, monetise the value, accept dilution), or do nothing (lose the right's value through dilution — the worst outcome). The "do nothing" trap is the single most common retail mistake.

Adoption, debate & evidence

The empirical landscape is unusually clear on two points.

First, the paradox: direct flotation costs of rights offerings are lower than underwritten public offerings, yet the rights method — once dominant for U.S. public companies — has nearly vanished there. Eckbo and Masulis report that since 1980 only about 2.5% of U.S. public industrial equity issuers used rights (rather than firm-commitment underwriting). Their adverse-selection framework is the leading explanation: a rights offer is cheapest only if current shareholders are expected to subscribe and hold; once they are likely to sell their rights to outsiders, the method loses its certification advantage and a reputable underwriter's "stamp of quality" becomes worth its higher fee. Underwriter certification and current-shareholder take-up are treated as substitute mechanisms; the propensity to use standby underwriting rises as expected take-up falls.

Second, the announcement reaction: equity issuance generally signals that management may view shares as fully or over-valued, producing negative abnormal returns. The seminal U.S. studies (Asquith & Mullins 1986; Masulis & Korwar 1986) document roughly a −3% average two-day announcement effect for seasoned common-stock issues. For rights issues specifically, reported effects are typically smaller and more variable across markets — e.g., UK two-day excess returns near −1.3% (Levis 1995) and −1.9% (Slovin et al. 2000) — and several authors note the strong negative reaction is largely a U.S. phenomenon, with some European/Asian markets showing positive or insignificant reactions. Treat any single percentage as study-specific, not a universal constant; the direction (typically negative/dilutive in the U.S.) is far more robust than the magnitude.

Strengths & limitations

Strengths. Protects incumbents from dilution; low direct cost; broad, fast access to a known, aligned investor base; avoids the discount and lock-up dynamics of placing stock with new institutions; renounceable structures give non-participants a way out.

Limitations / failure modes. The price drop and negative signalling can be severe, especially for distressed "rescue" issues. Take-up risk means an unsubscribed offering can fail without a backstop — hence underwriting fees that erode the cost advantage. For retail holders, the mechanics are easy to mishandle: the #1 misuse is passively ignoring a renounceable rights issue, which destroys value the holder could have captured by selling the nil-paid rights. A second pitfall is misreading the TERP-driven price drop on the ex-rights date as a "crash" rather than a mechanical adjustment.

Sources

Flags / disputes: announcement-effect magnitudes vary widely by study, market, and era — only the direction is robust, and even that (strongly negative) is mainly a U.S. result. The formula for the value of a right is a textbook approximation; traded nil-paid rights prices deviate due to time value and liquidity. The ~−3% (Asquith-Mullins / Masulis-Korwar) and UK rights figures are drawn from survey/summary papers, not re-verified against the primary tables, so treat the exact magnitudes as indicative.